Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

British Journal of Haematology

Volumn 159, Issue 4, 2012, Pages 430-440

  Steinbrunn, Torsten ^a   Stühmer, Thorsten ^a   Sayehli, Cyrus ^a   Chatterjee, Manik ^a   Einsele, Hermann ^a   Bargou, Ralf C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Akt; MAPK; MEK; Myeloma; PI3K; RAS

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; AKTI 12; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; MULTIPLE MYELOMA; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

APOPTOSIS; CELL LINE, TUMOR; ENZYME INHIBITORS; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS;

EID: 84868198690     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12039     Document Type: Article

References (35)

1. Annunziata, C.M., Hernandez, L., Davis, R.E., Zingone, A., Lamy, L., Lam, L.T., Hurt, E.M., Shaffer, A.L., Kuehl, W.M. & Staudt, L.M. (2011) A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood, 117, 2396-2404.
2. Bezieau, S., Devilder, M.C., Avet-Loiseau, H., Mellerin, M.P., Puthier, D., Pennarun, E., Rapp, M.J., Harousseau, J.L., Moisan, J.P. & Bataille, R. (2001) High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Human Mutation, 18, 212-224.
3. Carpten, J.D., Faber, A.L., Horn, C., Donoho, G.P., Briggs, S.L., Robbins, C.M., Hostetter, G., Boguslawski, S., Moses, T.Y., Savage, S., Uhlik, M., Lin, A., Du, J., Qian, Y.W., Zeckner, D.J., Tucker-Kellogg, G., Touchman, J., Patel, K., Mousses, S., Bittner, M., Schevitz, R., Lai, M.H., Blanchard, K.L. & Thomas, J.E. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 448, 439-444.
4. Chang, H., Qi, X.Y., Claudio, J., Zhuang, L., Patterson, B. & Stewart, A.K. (2006) Analysis of PTEN deletions and mutations in multiple myeloma. Leukemia Research, 30, 262-265.
5. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467-472.
6. Chatterjee, M., Stühmer, T., Herrmann, P., Bommert, K., Dörken, B. & Bargou, R.C. (2004) Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood, 104, 3712-3721.
7. Dai, Y., Chen, S., Pei, X.Y., Almenara, J.A., Kramer, L.B., Venditti, C.A., Dent, P. & Grant, S. (2008) Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood, 112, 2439-2449.
8. Engelman, J.A., Chen, L., Tan, X., Crosby, K., Guimaraes, A.R., Upadhyay, R., Maira, M., McNamara, K., Perera, S.A., Song, Y., Chirieac, L.R., Kaur, R., Lightbown, A., Simendinger, J., Li, T., Padera, R.F., Garcia-Echeverria, C., Weissleder, R., Mahmood, U., Cantley, L.C. & Wong, K.K. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine, 14, 1351-1356.
9. Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N.C., Chauhan, D., Richardson, P.G. & Anderson, K.C. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107, 4053-4062.
10. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G. & Anderson, K.C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 7, 585-598.
11. Hoeflich, K.P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., Zhou, W., Berry, L., Murray, L., Amler, L., Belvin, M., Friedman, L.S. & Lackner, M.R. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clinical Cancer Research, 15, 4649-4664.
12. Hsu, J., Shi, Y., Krajewski, S., Renner, S., Fisher, M., Reed, J.C., Franke, T.F. & Lichtenstein, A. (2001) The AKT kinase is activated in multiple myeloma tumor cells. Blood, 98, 2853-2855.
13. Hyun, T., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J.S. & Li, W. (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood, 96, 3560-3568.
14. Ismail, S.I., Mahmoud, I.S., Msallam, M.M. & Sughayer, M.A. (2009) Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leukemia Research, 34, 824-826.
15. Kim, K., Kong, S.Y., Fulciniti, M., Li, X., Song, W., Nahar, S., Burger, P., Rumizen, M.J., Podar, K., Chauhan, D., Hideshima, T., Munshi, N.C., Richardson, P., Clark, A., Ogden, J., Goutopoulos, A., Rastelli, L., Anderson, K.C. & Tai, Y.T. (2010) Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. British Journal of Haematology, 149, 537-549.
16. Kyle, R.A. & Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 2962-2972.
17. Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N.E., Greipp, P., Kyle, R.A., Oken, M.M. & Van Ness, B. (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88, 2699-2706.
18. Müller, C.I., Miller, C.W., Hofmann, W.K., Gross, M.E., Walsh, C.S., Kawamata, N., Luong, Q.T. & Koeffler, H.P. (2007) Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leukemia Research, 31, 27-32.
19. Palumbo, A. & Anderson, K. (2011) Multiple myeloma. New England Journal of Medicine, 364, 1046-1060.
20. Pei, X.Y., Dai, Y., Youssefian, L.E., Chen, S., Bodie, W.W., Takabatake, Y., Felthousen, J., Almenara, J.A., Kramer, L.B., Dent, P. & Grant, S. (2011) Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood, 118, 5189-5200.
21. Pene, F., Claessens, Y.E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C. & Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 21, 6587-6597.
22. Podar, K., Chauhan, D. & Anderson, K.C. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 23, 10-24.
23. Samuels, Y. & Waldman, T. (2010) Oncogenic mutations of PIK3CA in human cancers. Current Topics in Microbiology and Immunology, 347, 21-41.
24. San Miguel, J.F. & Mateos, M.V. (2011) Can multiple myeloma become a curable disease? Haematologica, 96, 1246-1248.
25. Savino, R., Ciapponi, L., Lahm, A., Demartis, A., Cabibbo, A., Toniatti, C., Delmastro, P., Altamura, S. & Ciliberto, G. (1994) Rational design of a receptor super-antagonist of human interleukin-6. EMBO Journal, 13, 5863-5870.
26. Shimizu, T., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Smith, L.S., Gunn, S., Smetzer, L., Mays, T.A., Kaiser, B., Wick, M.J., Alvarez, C., Cavazos, A., Mangold, G.L. & Patnaik, A. (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clinical Cancer Research, 18, 2316-2325.
27. Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M. & Bargou, R.C. (2011) Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood, 117, 1998-2004.
28. Stengel, C., Cheung, C.W., Quinn, J., Yong, K. & Khwaja, A. (2012) Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia, doi: 10.1038/leu.2012.1069.
29. Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R.A., Daniel, P.T., Bommert, K., Vassilev, L.T. & Bargou, R.C. (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood, 106, 3609-3617.
30. Stühmer, T., Zöllinger, A., Siegmund, D., Chatterjee, M., Grella, E., Knop, S., Kortüm, M., Unzicker, C., Jensen, M.R., Quadt, C., Chène, P., Schoepfer, J., García-Echeverría, C., Einsele, H., Wajant, H. & Bargou, R.C. (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia, 22, 1604-1612.
31. Tai, Y.T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.F., Rumizen, M., Burger, P., Morrison, A., Podar, K., Chauhan, D., Tassone, P., Richardson, P., Munshi, N.C., Ghobrial, I.M. & Anderson, K.C. (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 110, 1656-1663.
32. Vivanco, I. & Sawyers, C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer, 2, 489-501.
33. Wee, S., Jagani, Z., Xiang, K.X., Loo, A., Dorsch, M., Yao, Y.M., Sellers, W.R., Lengauer, C. & Stegmeier, F. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research, 69, 4286-4293.
34. Yu, K., Toral-Barza, L., Shi, C., Zhang, W.G. & Zask, A. (2008) Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biology & Therapy, 7, 307-315.
35. Zöllinger, A., Stühmer, T., Chatterjee, M., Gattenlöhner, S., Haralambieva, E., Müller-Hermelink, H.K., Andrulis, M., Greiner, A., Wesemeier, C., Rath, J.C., Einsele, H. & Bargou, R.C. (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood, 112, 3403-3411.